PMID- 30550794 OWN - NLM STAT- MEDLINE DCOM- 20191227 LR - 20191227 IS - 1873-7064 (Electronic) IS - 0028-3908 (Linking) VI - 148 DP - 2019 Apr TI - Nicotine enhances responding for conditioned reinforcement via alpha4beta2 nicotinic acetylcholine receptors in the ventral tegmental area, but not the nucleus accumbens or the prefrontal cortex. PG - 68-76 LID - S0028-3908(18)30440-4 [pii] LID - 10.1016/j.neuropharm.2018.12.011 [doi] AB - Nicotine enhances the conditioned reinforcing properties of reward-paired cues. We investigated the role of the ventral tegmental area (VTA), nucleus accumbens (NAcc), and prelimbic (PrL) and infralimbic (IL) cortices in mediating this enhancement. Male Long-Evans rats were implanted with bilateral guide cannulae aimed at either the VTA, NAcc, PrL or IL cortex. Next, rats underwent 12 sessions of Pavlovian conditioning. Each session consisted of 30 trials wherein a 5 s conditioned stimulus (CS) was paired with water (0.05 ml). Tests of responding for conditioned reinforcement were conducted during which presentation of the CS, now acting as a conditioned reinforcer (CRf), was contingent upon pressing one of two levers (CRf lever). Pressing the other lever had no consequences (NCRf lever). To determine if nicotinic acetylcholine receptors (nAChRs) in the VTA, NAcc, PrL cortex, or IL cortex mediate nicotine-enhanced responding for a CRf, the alpha4beta2 nAChR antagonist Dihydro-Beta-Erythroidine (DHbetaE; 10 nmol/0.5 muL) was infused into the respective areas prior to a systemic nicotine injection (0.2 mg/kg; SC). DHbetaE infused into the VTA, NAcc, or IL cortex, but not PrL cortex, attenuated nicotine-enhanced responding for a CRf. Next, to confirm that nAChRs in the VTA, NAcc, or IL cortex mediate this enhancement, nicotine (8, 16, or 32 nmol/0.5 muL) was infused into the respective areas. Nicotine infused into the VTA, but not NAcc or IL cortex, enhanced responding for a CRf. These findings suggest that nicotine primarily acts on alpha4beta2 nAChRs in the VTA to potentiate the conditioned reinforcing properties of reward-related cues. CI - Copyright (c) 2018 Elsevier Ltd. All rights reserved. FAU - Tabbara, Rayane I AU - Tabbara RI AD - Section of Biopsychology and Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, 250 College St., M5T 1R8, Toronto, ON, Canada; Department of Psychology, University of Toronto, 100 St. George St., M5S 3G3, Toronto, ON, Canada. Electronic address: rayane.tabbara@mail.utoronto.ca. FAU - Fletcher, Paul J AU - Fletcher PJ AD - Section of Biopsychology and Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, 250 College St., M5T 1R8, Toronto, ON, Canada; Department of Psychology, University of Toronto, 100 St. George St., M5S 3G3, Toronto, ON, Canada; Department of Psychiatry, University of Toronto, 250 College St., M5T 1R8, Toronto, ON, Canada. LA - eng GR - CIHR/Canada PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20181211 PL - England TA - Neuropharmacology JT - Neuropharmacology JID - 0236217 RN - 0 (Nicotinic Agonists) RN - 0 (Nicotinic Antagonists) RN - 0 (Receptors, Nicotinic) RN - 0 (nicotinic receptor alpha4beta2) RN - 23255-54-1 (Dihydro-beta-Erythroidine) RN - 6M3C89ZY6R (Nicotine) SB - IM MH - Animals MH - Conditioning, Classical/drug effects MH - Conditioning, Operant/drug effects/*physiology MH - Dihydro-beta-Erythroidine/pharmacology MH - Dose-Response Relationship, Drug MH - Male MH - Nicotine/*pharmacology MH - Nicotinic Agonists/pharmacology MH - Nicotinic Antagonists/pharmacology MH - Nucleus Accumbens/drug effects/*physiology MH - Prefrontal Cortex/drug effects/*physiology MH - Rats MH - Receptors, Nicotinic/*physiology MH - Reinforcement, Psychology MH - Self Administration MH - Ventral Tegmental Area/drug effects/*physiology OTO - NOTNLM OT - Infralimbic cortex OT - Nucleus accumbens OT - Prelimbic cortex OT - Rat OT - Reinforcement OT - Ventral tegmental area EDAT- 2018/12/15 06:00 MHDA- 2019/12/28 06:00 CRDT- 2018/12/15 06:00 PHST- 2018/07/30 00:00 [received] PHST- 2018/12/04 00:00 [revised] PHST- 2018/12/09 00:00 [accepted] PHST- 2018/12/15 06:00 [pubmed] PHST- 2019/12/28 06:00 [medline] PHST- 2018/12/15 06:00 [entrez] AID - S0028-3908(18)30440-4 [pii] AID - 10.1016/j.neuropharm.2018.12.011 [doi] PST - ppublish SO - Neuropharmacology. 2019 Apr;148:68-76. doi: 10.1016/j.neuropharm.2018.12.011. Epub 2018 Dec 11.